ABL shareholder Advanced Biological Laboratories cuts ABL Diagnostics stake to 93.58%, voting rights at 95.9%

• Advanced Biological Laboratories notified ABL Diagnostics on July 10, 2026 that it fell below the 95% capital threshold.
• ABL now holds 93.58% of the capital, 95.9% of the voting rights following block trades executed since 2025.
• Move supports ABL’s free-float expansion strategy, aimed at broader ownership, improved liquidity, greater market visibility.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260714239133) on July 15, 2026, and is solely responsible for the information contained therein.